Trial · NCT02043652
Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil
NCT02043652, Not applicable, Completed, Centers for Disease Control and Prevention; results first posted 2018-02-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil. Trials, record NCT02043652. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02043652
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil
- NCT number
- NCT02043652
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 119 participants, actual
- Lead sponsor
- Centers for Disease Control and Prevention
- Conditions
- Malaria
- Interventions
- Chloroquine, Primaquine
- First posted
- 2014-01-23
- Last updated
- 2018-02-07
- Results first posted
- 2018-02-07
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients With Adequate Clearance of Parasites and Symptoms | 28 days | Investigators, according to WHO guidelines, will evaluate patients at regular intervals to evaluate symptom and parasitemia clearance. |
| Secondary | Number of Patients Reporting Relapses | 6 months | Evaluate the relapse rate, that is reappearance of parasites, for up to 6 months after treatment. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients With Adequate Clearance of Parasites and Symptoms | 28 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Patients Reporting Relapses | 6 months | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Adequate Clearance of Parasites and Symptoms | Chlorquine and Primaquine | 110 | Participants | ||
| Number of Patients Reporting Relapses | Chlorquine and Primaquine | 28 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Chloroquine and Primaquine | 119 | |
| Overall Study | COMPLETED | Chloroquine and Primaquine | 93 | |
| Overall Study | NOT COMPLETED | Chloroquine and Primaquine | 26 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Chlorquine and Primaquine | ||
| Total, other adverse events | Chlorquine and Primaquine | 0 | 119 |
| Total, serious adverse events | Chlorquine and Primaquine | 0 | 119 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02043652
GET https://conductscience.org/api/trials/v1/NCT02043652/registered